Aktis Oncology offers a high-risk, high-upside radiopharmaceutical platform story: strong cash runway, Lilly validation, promising early dosimetry, and major solid-tumor ambitions balanced against clinical, isotope-supply, and dilution risks.
Overview
Aktis Oncology is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for major solid tumors through its isotope-agnostic miniprotein radioconjugate platform. Its lead assets, AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, are in Phase 1b development. Revenue currently comes solely from collaboration and licensing agreements, especially Eli Lilly. The platform aims to combine antibody-like specificity with rapid tumor penetration and fast systemic clearance, potentially reducing marrow, kidney, and salivary toxicity while expanding radiopharmaceutical use into large tumor populations.